Search alternatives:
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
ann decrease » nn decrease (Expand Search), a decrease (Expand Search), gain decreased (Expand Search)
_ ann » _ any (Expand Search), _ anc (Expand Search)
Showing 1 - 20 results of 2,997 for search '(( auc largest decrease ) OR ((( _ large decrease ) OR ( _ ann decrease ))))', query time: 0.32s Refine Results
  1. 1
    ANN architecture.

    ANN architecture. by Abdelfattah Dani (22226715)

    Published 2025
    Save to List
    Saved in:
  2. 2
    ANN architecture and configuration.

    ANN architecture and configuration. by Abdelfattah Dani (22226715)

    Published 2025
    Save to List
    Saved in:
  3. 3
    Illustration of BSC control using ANN for WECS.

    Illustration of BSC control using ANN for WECS. by Abdelfattah Dani (22226715)

    Published 2025
    Save to List
    Saved in:
  4. 4
    Performance comparison between the OTC-FOC and ANN-BSC.

    Performance comparison between the OTC-FOC and ANN-BSC. by Abdelfattah Dani (22226715)

    Published 2025
    Save to List
    Saved in:
  5. 5
    Training process flowchart of ANN-based MPPT controller.

    Training process flowchart of ANN-based MPPT controller. by Abdelfattah Dani (22226715)

    Published 2025
    Save to List
    Saved in:
  6. 6
    THD for the stator current i<sub>sb</sub> (ANN-BSC).

    THD for the stator current i<sub>sb</sub> (ANN-BSC). by Abdelfattah Dani (22226715)

    Published 2025
    Save to List
    Saved in:
  7. 7
    ANN-BSC outcomes: (a) PMSG currents, (b) Zoom-in illustration.

    ANN-BSC outcomes: (a) PMSG currents, (b) Zoom-in illustration. by Abdelfattah Dani (22226715)

    Published 2025
    Save to List
    Saved in:
  8. 8
    Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection.

    Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. by Ryan J. Treves (13527735)

    Published 2025
    Save to List
    Saved in:
  9. 9
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 10
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: